Immunovent

Immunovent is a private, pre-revenue diagnostics company developing a novel, needle-free allergy testing platform called LAMB-Dx. The technology involves a gentle mucosal brush sample from symptomatic areas, coupled with a proprietary assay, to provide more accurate local allergy diagnoses, particularly for patients misdiagnosed by conventional methods. The company has completed proof-of-concept studies, is optimizing protocols, and anticipates launching its first diagnostic product, targeting a significant portion of the $1.2 billion annual allergy testing market where current methods fail up to 20% of symptomatic patients.

Patented Local Antibody Mucosal Brush Diagnostic (LAMB-Dx) platform. Combines a gentle mucosal brush sampling procedure from symptomatic areas (nose/mouth) with a proprietary assay to detect antigen-specific IgE directly from local epithelial cells, aiming for more accurate allergy diagnosis than systemic blood or skin tests.

Immunovent competes against entrenched standard-of-care diagnostics: skin prick tests and serum-specific IgE blood tests offered by large companies like Thermo Fisher Scientific (ImmunoCAP) and Siemens Healthineers. Its differentiation is direct local measurement, but it must displace these cheaper, familiar tests and may face future competition from other novel local testing approaches.